HMG CoA (β-hydroxy-β-methylglutaryl coenzyme A) reductase inhibitors are very effective in lowering total and low-density lipoprotein cholesterol. The incidence of adverse effects is very low with elevated transaminase levels and myopathy being of greatest concern. Administration of these drugs in combination with colestipol has produced a reduction in coronary artery stenosis and cardiovascular events.